# EDGAR Filing Document

**Accession Number:** 0001688757
**File Stem:** 0001688757-26-000031
**Filing Date:** 2026-4
**Character Count:** 8707
**Document Hash:** 88f127045d95ec12974f7073d5295256
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001688757-26-000031.hdr.sgml**: 20260424

**ACCESSION NUMBER**: 0001688757-26-000031

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260424

**DATE AS OF CHANGE**: 20260424

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ESTABLISHMENT LABS HOLDINGS INC.
- **CENTRAL INDEX KEY:** 0001688757
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 981436377
- **STATE OF INCORPORATION:** D8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38593
- **FILM NUMBER:** 26894898

**BUSINESS ADDRESS:**
- **STREET 1:** BUILDING B15 AND 25 COYOL FREE ZONE
- **CITY:** ALAJUELA
- **STATE:** G2
- **ZIP:** 20101
- **BUSINESS PHONE:** 50624342400

**MAIL ADDRESS:**
- **STREET 1:** BUILDING B15 AND 25 COYOL FREE ZONE
- **CITY:** ALAJUELA
- **STATE:** G2
- **ZIP:** 20101

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

**PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE <br>SECURITIES EXCHANGE ACT OF 1934**

Filed by the Registrant ⌧

Filed by a party other than the Registrant ◻

Check the appropriate box:

◻&nbsp;&nbsp;&nbsp;&nbsp;Preliminary Proxy Statement

◻&nbsp;&nbsp;&nbsp;&nbsp;**Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

◻&nbsp;&nbsp;&nbsp;&nbsp;Definitive Proxy Statement

⌧&nbsp;&nbsp;&nbsp;&nbsp;Definitive Additional Materials

◻&nbsp;&nbsp;&nbsp;&nbsp;Soliciting Material under §240.14a-12

**Establishment Labs Holdings Inc.**

**(Name of Registrant as Specified In Its Charter)**

Payment of Filing Fee (Check all boxes that apply):

⌧&nbsp;&nbsp;&nbsp;&nbsp;No fee required

◻&nbsp;&nbsp;&nbsp;&nbsp;Fee paid previously with preliminary materials

◻&nbsp;&nbsp;&nbsp;&nbsp;Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

------

**ESTABLISHMENT LABS HOLDINGS INC.**

**SUPPLEMENT TO PROXY STATEMENT**

**FOR 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS**

**To be held at 1:00 p.m., Eastern Time, on Friday, May 22, 2026**

This proxy statement supplement, dated April 24, 2026 (this "Supplement"), supplements the definitive proxy statement on Schedule 14A of Establishment Labs Holdings Inc. (the "Company"), dated April 10, 2026 (the "Proxy Statement"), for the Company's Annual Meeting of Shareholders to be held on May 22, 2026 (the "Annual Meeting").

**THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT. EXCEPT AS SPECIFICALLY SUPPLEMENTED BY THE INFORMATION CONTAINED HEREIN, THIS SUPPLEMENT DOES NOT MODIFY ANY OTHER INFORMATION SET FORTH IN THE PROXY STATEMENT.**

***Explanatory Note***

The Company is filing this proxy supplement to correct a typographical error contained in the "2025 Non-Employee Director Compensation" table included in the *Non-Employee Director Compensation* section of the Proxy Statement, which incorrectly reported the stock awards that Juan José Chacón Quirós, Ann Custin, Leslie Gillin, Nicholas Lewin, Edward J. Schutter, and Bryan Slotkin received as $374,946. The correct amount of stock awards that Juan José Chacón Quirós received is $499,975 and that Ann Custin, Leslie Gillin, Nicholas Lewin, Edward J. Schutter, and Bryan Slotkin received is $124,984, which also results in a change to Mr. Quirós, Ms. Custin, Ms. Gillin, Mr. Lewin, Mr. Schutter, and Mr. Slotkin's total compensation amounts. Accordingly, the Proxy Statement disclosure under the heading *Non-Employee Director Compensation* is amended and replaced in its entirety with the following disclosure.

**2025 NON-EMPLOYEE DIRECTOR COMPENSATION**

The following table presents the total compensation for each person who served as a non-employee member of our Board during 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Fees Earned or Paid in Cash**<sup>(1)</sup> | **Stock Awards** <sup>(2) (3)</sup> | **Option Awards** <sup>(2) (3)</sup> | **Total** |
| Juan José Chacón Quirós <sup>(4)</sup> | $*33333* | $*499975* | $*374991* | $*908299* |
| Dennis Condon <sup>(5)</sup> | $*13750* | $*—* | $*—* | $*13750* |
| Ann Custin | $*82444* | $*124984* | $*—* | $*207428* |
| Leslie Gillin | $*67500* | $*124984* | $*—* | $*192484* |
| Nicholas Lewin <sup>(6)</sup> | $*100000* | $*124984* | $*906223* | $*1131207* |
| Edward J. Schutter | $*75000* | $*124984* | $*—* | $*199984* |
| Bryan Slotkin | $*65000* | $*124984* | $*—* | $*189984* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(1)&nbsp;&nbsp;&nbsp;&nbsp;In 2025, all directors except for Mr. Chacón Quirós elected to receive their quarterly fees in shares. The amounts listed reflect the total fair value of the shares as granted, which is based on the stock value at the end of each quarter and the total fees in cash earned each quarter by each director.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(2)&nbsp;&nbsp;&nbsp;&nbsp;The aggregate grant date fair value of these awards was computed in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 718 and excludes the effects of estimated forfeitures. The reported award values have been determined using the assumptions described in Note 10 to the Consolidated Financial Statements included in our 2025 Annual Report.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(3)&nbsp;&nbsp;&nbsp;&nbsp;The following chart sets forth the number of outstanding awarded restricted stock units (unvested) and stock options (unexercised) held by each non-employee director as of December 31, 2025. For Mr. Chacón Quirós, the amounts reported include all of his outstanding equity awards, whether granted in connection with his services as an employee or non-employee director.*

------

---

| | | |
|:---|:---|:---|
| **Name** | **Outstanding Restricted Stock Units** <sup>(7)</sup> | **Outstanding Stock Options** |
| Juan José Chacón Quirós | 30209 | 197130 |
| Dennis Condon  |  | 24890 |
| Ann Custin | 3413 | 12000 |
| Leslie Gillin | 3413 | 12000 |
| Nicholas Lewin  | 31169 | 93856 |
| Edward J. Schutter | 3413 | 66780 |
| Bryan Slotkin | 3413 | 12000 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(4)&nbsp;&nbsp;&nbsp;&nbsp;Mr. Chacón Quirós formally terminated his non-director employment with the Company effective April 30, 2025. For Mr. Chacón Quirós, the amount reported in the Option Awards column includes the May 2025 grant for 14,906 stock options with an exercise price of $36.46 and 10,285 restricted stock units granted in consideration for advisory and advocacy services he performs for the Company in addition to his service as a non-employee director. This grant will vest over four years upon award. The May 23, 2025 grant for 3,413 restricted share units was granted for his services as a director. The executive compensation tables that follow describe and quantify Mr. Chacón Quirós compensation as our Chief Executive Officer, as a non-employee director and consultant.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(5)&nbsp;&nbsp;&nbsp;&nbsp;Mr. Condon served on the Board until his passing in January 2025.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(6)&nbsp;&nbsp;&nbsp;&nbsp;For Mr. Lewin, the amount reported in the Option Awards column includes a May 2025 grant for 36,027 stock options with an exercise price of $36.46 granted in consideration for consulting services he performs for the Company in addition to his service as a non-employee director. This grant will vest over four years upon award.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(7)&nbsp;&nbsp;&nbsp;&nbsp;For Mr. Lewin, the outstanding restricted stock units include a performance-based award granted in May 2023 for 27,756 shares vesting based on achievement of certain market conditions and continuing services for the Company.*

***Voting Matters***

Please note that any proxy or voting instructions you have submitted for the Annual Meeting are still valid and will be used to vote your shares at the Annual Meeting. **If you have already submitted your vote, you do not need to take any further action** unless you intend to change or revoke your previous proxy or voting instructions. Information on how to vote your shares and how to change your vote or revoke your proxy or voting instructions is contained in the Proxy Statement. The Company urges shareholders to vote their shares prior to the Annual Meeting by using one of the methods described in the Proxy Statement.

<br>